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Summary
MiRNAs are fine-tuning modifiers of skeletal muscle regulation,
but knowledge of their hormonal control is lacking. We used a
co-twin case–control study design, that is, monozygotic post-
menopausal twin pairs discordant for estrogen-based hormone
replacement therapy (HRT) to explore estrogen-dependent
skeletal muscle regulation via miRNAs. MiRNA profiles were
determined from vastus lateralis muscle of nine healthy 54–62-
years-old monozygotic female twin pairs discordant for HRT
(median 7 years). MCF-7 cells, human myoblast cultures and
mouse muscle experiments were used to confirm estrogen’s
causal role on the expression of specific miRNAs, their target
mRNAs and proteins and finally the activation of related
signaling pathway. Of the 230 miRNAs expressed at detectable
levels in muscle samples, qPCR confirmed significantly lower
miR-182, miR-223 and miR-142-3p expressions in HRT using than
in their nonusing co-twins. Insulin/IGF-1 signaling emerged one
common pathway targeted by these miRNAs. IGF-1R and FOXO3A
mRNA and protein were more abundantly expressed in muscle
samples of HRT users than nonusers. In vitro assays confirmed
effective targeting ofmiR-182 andmiR-223 on IGF-1R and FOXO3A
mRNA as well as a dose-dependent miR-182 and miR-223 down-
regulations concomitantlywith up-regulation of FOXO3A and IGF-
1R expression. Novel finding is the postmenopausal HRT-reduced
miRs-182, miR-223 and miR-142-3p expression in female skeletal
muscle. The observedmiRNA-mediated enhancement of the target
genes’ IGF-1R and FOXO3A expression as well as the activation of
insulin/IGF-1 pathway signaling via phosphorylation of AKT and
mTOR is an important mechanism for positive estrogen impact on
skeletal muscle of postmenopausal women.
Key words: aging; AKT; FOXO3A; IGF-1 signaling; IGF-1R;
menopause; miR-142-3p; miR-182; miR-223; mTOR; phosphor-
ylation.
Introduction
Menopause results from the loss of ovarian function and is defined as a
natural cessation ofmenstruation that usually occurs after the fifth decade
of a woman’s life. Consequently, women spend more than one-third of
their lives in postmenopausal status. The menopausal decline in estrogen
can have wide-ranging effects on women’s health, as it contributes to
decreased bonemass and density (Riggs et al., 2002), to the accumulation
and redistribution of adipose tissue (Tchernof et al., 2004) and to
increased risk for metabolic disorders and cardiovascular diseases (Carr,
2003). Furthermore, growing evidence indicates that age-related changes
in hormonal status play a role in the pathogenesis of sarcopenia (Kamel
et al., 2002). A low level ofmusclemass and strength increases the risk for
type II diabetes andmay lead to functional disability and loss of autonomy
andfinally to premature death. Toprevent and treat sarcopenia effectively,
the background molecular mechanisms need to be known.
The role of estrogen during growth and development is clear: in
interaction with other hormones, it is essential for bone and muscle
development where it delivers its effects via specific receptors. However,
the role of estrogen in aging muscle is not as well understood as it is in
bone. A recent meta-analysis, nevertheless, concluded that as a result of
improved muscle quality rather than muscle hypertrophy, postmeno-
pausal women using hormone replacement therapy (HRT) had ~5%
greater muscle strength than those not using HRT (Greising et al., 2009).
It has been suggested that a low postmenopausal circulating estrogen
level with increased pro-inflammatory cytokines is an indirect mechanism
in the progression of sarcopenia (Roubenoff, 2003). Furthermore,
estrogen can also have a direct effect on muscle metabolism, as
estrogen receptors, along with the enzymes needed for local estrogen
synthesis, are expressed in skeletal muscle (Lemoine et al., 2003; Wiik
et al., 2003; P€oll€anen et al., 2011). Our previous studies have shown
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that HRT has favorable effects on lean body mass, muscle mass and
performance during early postmenopausal years (Sipil€a et al., 2001;
Taaffe et al., 2005) and that long-term HRT use is associated with better
mobility, greater muscle power and favorable body and muscle
composition (Ronkainen et al., 2009). Some of the benefits of HRT
may be implemented through the muscular IGF-1-pathway, the activity
of which we have recently observed to be higher in HRT users than
nonusers (P€oll€anen et al., 2010; Ahtiainen et al., 2012a). The IGF-
1-pathway plays a central role in muscle mass regulation, as it activates
protein synthesis and inhibits protein degradation (Velloso, 2008).
Therefore, modulation of the IGF system is potential strategy to improve
muscle condition in older adults.
Recently, a class of evolutionary conserved small noncoding RNAs,
termed microRNAs (miRNAs), has been characterized (Lim et al., 2005).
MiRNAs bind to the 30UTR of target mRNAs and either block the
translation of the message or bind to the open reading frame and target
the mRNA transcript for degradation. The actions of miRNAs are
sequence- or motif-specific but not gene-specific. Consequently, the
dysregulation of miRNA expression can lead to alterations in the
expression of hundreds of mRNAs and proteins. During the past few
years, the regulation of miRNAs by estrogen has been confirmed, not in
healthy human tissue but in breast cancer tissue and/or breast cancer
cells (Le Quesne & Caldas, 2010). In normal mouse cells, estradiol has
been shown to modulate miRNA expression (Dai et al., 2008). With
respect to skeletal muscle, recent findings support the hypothesis that
key aspects of muscle biology are subject to regulation by muscle-
specific myomiRNAs (van Rooij et al., 2009; Carvajal & Rigby, 2010). It is
highly likely that hormones play an important role in regulating the
expression of miRNAs in muscle and therefore in regulating of muscle
properties. However, to date, no previous studies have attempted to
identify estrogen-responsive miRNAs in skeletal muscle or any other
healthy human tissue. The identification and characterization of estro-
gen-regulated miRNAs can be expected to provide new biomarkers and
therapeutic targets in the aging body as well as in aging-related
disorders, including sarcopenia.
In the present study, we sought to identify estrogen-regulated
miRNAs and their mRNA/protein targets in the skeletal muscle tissue of
nine healthy, postmenopausal monozygotic (MZ) female twin pairs
discordant for HRT. This design enables us to study the differences
between HRT users and nonusers independently of interindividual
sequence-level genetic variability. In addition to genetic factors,
co-twins also share a number of environmental factors, starting from
their intrauterine environment and continuing throughout childhood.
The results from human studies were finally confirmed in vitro with
human muscle cell experiments and by using mouse mature muscle cells
in culture.
Results
Participant characteristics
Table 1 presents the participants’ body composition and hormonal
status according to use of HRT. The mean age of the participants was
57.8  2 years. As expected, the concentration of 17b-estradiol (E2)
was on average five times higher in the HRT users than in their nonusing
co-twins (P = 0.003). Body fat percentage was smaller in the HRT users
than nonusers (P = 0.031). The relative muscle area in the cross section
of the thigh was larger (P = 0.009), and concomitantly, the relative fat
area was smaller (P = 0.009) in the HRT users than nonusers. In vertical
jumping test, 20% greater muscle power was observed in the HRT users
than in nonusers (P = 0.012). Furthermore, the participants did not differ
regarding diseases, physical activity, smoking behavior, alcohol con-
sumption, or daily energy intake expressed as% amount of energy
obtained from proteins, fat, or carbohydrates (Ronkainen et al., 2009).
Additionally, according to the questionnaires administrated for the
Finnish Twin Cohort in 1975, 1981, and 1990 (Kaprio & Koskenvuo,
2002), there were no differences in physical activity, smoking behavior,
or alcohol use between these HRT users and their nonusing co-twins.
MiRNA expression profile comparison in MZ twin pairs
discordant for HRT
To identify differentially expressed miRNAs in the skeletal muscle biopsy,
samples were screened for the expression of 365 miRNAs using
microarray assay. MiRNAs expressed at a detectable level in more than
80% of samples were included, and using this filtering criterion, 230
miRNAs were taken into the final analysis. The most highly expressed
miRNAs in the HRT nonusers, representing postmenopausal muscle at
baseline, are shown in Fig. 1A. MiR-133a, one of the specific myomiR-
NAs, proved to be the most abundant miRNA in skeletal muscle, with an
expression rate about 5000-fold greater than the median of all the
miRNAs expressed. Of the 230 miRNAs expressed at detectable levels,
only five showed higher than 1.5-fold changes (P < 0.05). MiR array
data showed miR-142-3p, miR-142-5p, miR-223, miR-182, and miR-451
to be hypo-expressed in the HRT users compared to nonusers (Fig. 1B).
Validation by quantitative PCR (qPCR) confirmed that the expression
levels of miR-182, miR-223, and miR-142-3p in the HRT users were
approximately one-third of that of nonusers (P = 0.05, 0.001 and 0.003,
respectively; Fig. 1C), while miR-142-5p and miR-451 were not signif-
icantly different between HRT users and their nonuser co-twins.
Identification of putative common mRNAs and pathways
targeted by differentially expressed miRNAs
To identify putative mRNA target sequences shared by two or three of
the identified miRNAs, we used a simple Fortran program combining
miRNAs and related target predictions documented in the PicTar and
TargetScan databases (SID1.0, Albertini et al., 2011). Three putative
mRNA targets common to all three identified miRNAs were found:
FOXO1A, SOX11, and ZCCH14. In addition, pair-wise analyses revealed
42 common targets for miR-182 and miR-142-3p, 34 common targets
for miR-182 and miR-223, and 7 common targets for miR-142-3p and
miR-223 (Table S1, Fig. 2A).
Table 1 Basic characteristics of postmenopausal genetically identical twin sister
pairs from whom the other twin was a current HRT user (7.5  3.9 years), and
the co-twin had never used HRT. Data are expressed as means  SD. P-values
are obtained from paired-samples t-test
Variables
Nonuser
n = 9
HRT user
n = 9 P
Estradiol (pmol L1) 35.3  29.7 190.9  220.5 0.003
BMI (kg m2) 26.5  5.0 24.7  3.5 0.153
Percentage fat (%) 33.3  7.9 28.8  6.4 0.031
Relative muscle area in
thigh cross section (%)
52.1  11.0 56.3  8.8 0.009
Relative fat area in thigh
cross section (%)
47.9  11.0 43.7  8.8 0.009
Muscle power: vertical
jumping height (cm)
13.7  4.4 16.5  2.9 0.012
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Identification of common pathways targeted by miR-182, miR-223,
and miR-142-3p was obtained using the DIANA-microT 3.0 target
prediction program (http://diana.cslab.ece.ntua.gr/microT/), which has
been shown to have the highest ratio of correctly predicted targets over
other prediction tools (Maragkakis et al., 2009). DIANA-microT 3.0
calculates the miRNA-targeted gene score -log(P value), which reflects
the weighted sum of the scores of all the conserved and nonconserved
miRNA recognition elements on the 30UTR of the target mRNA, and this
score was also indicated for clusters of miRs. This score has been
demonstrated to correlate well with fold changes in suppression of
protein expression (Maragkakis et al., 2009; Satoh & Tabunoki, 2011).
Putative pathways affected by miR-182, miR-223, and miR-142-3p are
reported in Table 2. Among the putative target pathways, we found the
insulin/IGF1 pathway (Fig. 2B). As recently we reported that estrogen-
based hormone therapy is associated with increased activity in the same
pathway (P€oll€anen et al., 2010; Ahtiainen et al., 2012a), we focused
here on IGF-1R, FOXO3A, and FOXO1A, which in our analysis proved to
be regulated by miR-182, miR-223, and miR-142-3p, as described in
Fig. 2.
mRNA and protein levels of putative miRNA targets in muscle
tissue of identical twins discordant for HRT
The mRNA levels of the putative miRNA target genes belonging to the
insulin/IGF-1 signalling pathway were analyzed by qPCR. The mean
transcript levels of IGF-1R, FOXO1A, and FOXO3A in the HRT users were
128%, 123%, and 181% of the mean values of their nonusing co-twins
(Fig. 2C). However, only IGF-1R and FOXO3A mRNAs tended to be or
were significantly higher in the HRT users (P = 0.060 and 0.039,
respectively), whereas FOXO1A mRNA was not significantly modulated
(Fig. 2C). Consequently, miR-142-3p was here excluded from the further
analyses, as it was not predicted to target other components of the
insulin/IGF-1 pathway.
Only limited amount of protein samples from muscle biopsies was
available. That was used to study the protein expression of IGF-1R and
FOXO3A (Fig. 2D and E). The mean protein level of IGF-1R in the HRT
users was 134% of the mean value of their nonusing co-twins (n = 9
pairs, P = 0.039). Also, the protein level of FOXO3A in the HRT users was
161% of the mean value of the nonusers (n = 3 pairs); however, there
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Fig. 1 Expression of miRNAs in skeletal muscle of postmenopausal MZ twin pairs. (A) The most highly expressed miRNAs in skeletal muscle of the co-twins not using HRT.
Data are normalized against the median relative expression value of all detectable miRNAs and expressed as the relative expression values in arbitrary unit (a.u.). MyomiRNAs
are presented in bold. (B) Differentially expressed miRNAs in the Applied Biosystems miRNA Array pool A in muscle samples of HRT using and nonusing MZ co-twins. Each bar
corresponds to the expression fold difference, calculated as DDCt, of the miR listed in the figure. (For detailed calculations for the values, see the experimental procedures
section). Data are reported as the mean value of three independent experiments. A 1.5-fold or greater difference with a P-value < 0.05 (paired-samples t-test) was
considered significant and reported in the figure. (C) Differentially expressed miRNAs in skeletal muscle of nonusers (white bar) and HRT users (black bar) as measured by
qPCR. Data were normalized against RNU44 expression levels. P values are from paired-samples t-test. *P ≤ 0.05, **P ≤ 0.01.
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were samples from only three pairs available which prohibited pair-wise
comparisons and statistically testing.
MiRNA regulation of IGF-1R, FOXO1A, and FOXO3A 30UTRs
FOXO3A and FOXO1A have been identified as direct targets for miR-182
(Guttilla & White, 2009; Segura et al., 2009). In the present study, we
demonstrated, using luciferase assay in HEK-293 cells, that IGF-1R also is
a target for miR-182 (Fig. 3A). We also demonstrated here that IGF-1R,
FOXO1A, and FOXO3A are direct targets for miR-223 (Fig. 3B, C, D).
Hence, the in silico prediction made with the SID1.0 software was
confirmed.
MiR-223 and miR-182 modulate IGF-1R, FOXO1A, and
FOXO3A protein levels
Previously, it has been shown that miR-182 over-expression represses
FOXO1A and FOXO3A in breast cancer and melanoma cells, respectively
(Guttilla & White, 2009; Segura et al., 2009). To determine the effects of
gain-of-function of miR-182/223, we used MCF-7 cells known to be
highly responsive to E2. Consequently, MCF-7 cells were transfected
with pCMV-MIR182, pCMV-MIR223, and pCMV-MIR (=empty or
scrumble vectors) to induce their overexpression and to analyze the
protein expression of their targets, that is, IGF-1R, FOXO3A, and
FOXO1A. We found that miR-182 over-expression represses IGF-1R and
FOXO3A in MCF-7 cells (P < 0.05), while the effects on FOXO1A protein
expression were milder (Fig. 4A and B). In line with this, transfection-
induced over-expression of mature miR-223 significantly inhibited IGF-1R
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Fig. 2 Putative common targets of the identified estrogen-responsive miRNAs and their putative role in the insulin/IGF1 signaling pathway. (A) Venn diagram showing the
common target genes of the identified miRNAs. The complete lists of all putative common targets are reported in Table S1. (B) Putative role of the target genes in insulin/IGF-
1 signaling pathway. (C) Gene expression of potential common miR-targets with significant role in the insulin/IGF-1 pathway in skeletal muscle of postmenopausal women.
Gene expression was measured by qPCR. (D) Western blot analyses of target proteins normalized against GAPDH. Protein levels were analyzed by densitometry and
normalized against GAPDH expression. (E) Representative Western blot images from three twin pairs always presenting first the nonuser followed with her HRT-using
co-twin. P values are from paired-samples t-test. *P ≤ 0.05.
Table 2 Common pathways of miR-142-3p, miR-182, and miR-223. KEGG
Pathway name, the identification ID, and miRNA-targeted gene score (log
(P-value) are shown. The database used for this analysis was DIANA-MicroT 3.0
KEGG Pathway name ID log(P-value)
Regulation of actin cytoskeleton hsa04810 17.66
Focal adhesion hsa04510 8.31
Colorectal cancer hsa05210 7.62
ErbB signaling pathway hsa04012 5.76
IGF1/Insulin signaling pathway hsa04910 4.85
Estrogen-regulated miRs in skeletal muscle, F. Olivieri et al. 853
ª 2014 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
and FOXO3A protein levels (P < 0.05), while milder effects on FOXO1A
protein expression were observed (Fig. 4C and D). In addition, the loss-
of-function of miR-223 resulted in an evident increase in the protein
expression of IGF-1R (Fig. 4E).
Estradiol regulates miR-182 and miR-223 expression and their
identified targets leading to activation of insulin/IGF-1
signaling pathway in MCF-7 cells
We used MCF-7 breast cancer cells to show that the identified miRNAs
are regulated by E2 stimulation. MCF-7 cells are one of the in vitro
models most widely used to study estrogen signaling, as they express
high levels of estrogen receptor alpha (ERa) and are strongly growth-
stimulated under exposure to E2. In MCF-7 cells, 10 (data not shown)
and 100 nM E2 treatment induced significant down-regulation of all
three miRNAs (P < 0.05 for all; Fig. 5A). E2 treatment also induced up-
regulation of IGF-1R and FOXO3A mRNA expression (Fig. 5B) as well as
up-regulated protein levels (Fig. 5C). Nevertheless, FOXO1A was not
significantly modulated. A dose-dependent effect was also observed in
protein levels (Fig. 5C). Furthermore, Western blot analyses showed
E2-induced increase in the phosphorylation of AKT in comparison with
untreated control cells (Fig. 5D).
Estradiol suppresses miRNA expression and activates insulin/
IGF-1 signaling pathway in human myoblasts and in mouse
mature muscle cells
To find out whether E2-mediated regulation of the expression of miRNAs
and their targets exists specifically in myogenic cells themselves, without
other cell types potentially present in muscle biopsies, we exposed
human myoblasts derived from quadriceps femoris muscle of a newborn
girl to E2. Both miR-223 and miR-142-3p were down-regulated by
100 nM E2, the difference being highly significant for miR-142-3p
(Fig. 6A). Concerning the miRNA targets (IGF-1R, FOXO3A and
FOXO1A), the expression of FOXO1A increased significantly at mRNA
level (Fig. 6B) and tended to increase at protein level (Fig. 6C and D).
Furthermore, an increase was found in both the phosphorylation of AKT
and mammalian target of rapamycin (mTOR) (Fig. 6E and F) in the
human myoblasts following exposure to E2. The phosphorylation of
mTOR was statistically significantly more abundant in E2-exposed muscle
cells than in mock-treated cells (P < 0.05).
To confirm the ability of E2 to activate insulin/IGF-1 signaling pathway
in skeletal muscle, we used mouse diaphragm muscle cells. We found
out that diaphragm muscle cells of young male mouse showed down-
regulation of both miR-182 and miR-223 under exposure to 100 nM
estradiol for 24 h (Fig. 7A) concomitantly with increased AKT phos-
phorylation (P < 0.05) (Fig. 7B).
Discussion
A co-twin case–control study design with postmenopausal MZ twin
sisters discordant for the use of long-term hormone replacement therapy
(HRT) was utilized to identify muscular estrogen-sensitive miRNAs and
their targets as a mechanism of skeletal muscle regulation by HRT. The
most noteworthy novel finding was that in skeletal muscle, HRT use
associates with down-regulation of miR-182, miR-223, and miR-142-3p,
which modulate the expression of central players in the insulin/IGF-1
pathway, namely IGF-1R and FOXO3A. This is in line with our previous
studies showing that postmenopausal HRT induces an up-regulation of
genes belonging to the IGF-1 signaling cascade (P€oll€anen et al., 2010;
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Fig. 3 Functional binding assays. (A) Binding of miR-182 to the 30UTR region of IGF-1R. (B) Binding of miR-223 to the 30UTR region of FOXO1A. (C) Binding of miR-223 to
the 30UTR region of IGF-1R. (D) Binding of miR-223 to the 30UTR region of FOXO3A. Each pLUC vector contains the CMV promoter, the firefly luciferase gene, the 30 UTR of
a target gene, and a SV40 terminator sequence. When a miRNA is expressed and binds to the 30 UTR, it results in repression of luciferase gene expression. We used pLUC
plasmids encoding for the 30-UTR regions of the mRNA targets IGF-1R, FOXO1A, and FOXO3A (pLUC IGF-1R, pLUC FOXO1A, and pLUC FOXO3A) and for the 30-UTR regions
of the same mRNA targets containing deletions (pLUC IGF-1R deletion, pLUC FOXO1A deletion, and pLUC FOXO3A deletion). Each pLUC vector was co-transfected into the
HEK293T cells with a plasmid-encoding Renilla luciferase along with a plasmid-encoding miR-182 or miR-223 or the empty vector. Also pSUPER-scramble oligos were used
for co-transfection into the HEK293T cells. No significant differences were observed when pSUPER-scramble oligos were used instead of empty vector. Firefly luciferase
values were normalized to Renilla luciferase activity, and the ratio of luciferase activity of each construct in the presence or in the absence of exogenous miR-182/-223 was
calculated. Data are reported as relative light units (RLU) and in relation to empty vector. Mean value  SD of three independent experiments are shown. *P ≤ 0.05 pLUC-
target vs. pLUC; #P ≤ 0.05 pLUC-target-deletion vs. pLUC. (For details see Experimental procedures).
Estrogen-regulated miRs in skeletal muscle, F. Olivieri et al.854
ª 2014 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Ahtiainen et al., 2012a) and with other studies showing that miR-182
represses FOXO3A (Guttilla & White, 2009; Segura et al., 2009). In
addition to repressing FOXO3A, we showed, for the first time, that miR-
182 also represses IGF-1R. Furthermore, we confirmed that miR-223 also
represses both IGF-1R and FOXO3A. In vitro analyses verified that
estrogen modulates IGF-1R and FOXO3A expression via miRNA down-
regulation as well as affects the activity of the insulin/IGF-1 pathway by
enhancing AKT and mTOR phosphorylation both in myoblasts and in
mature muscle cells. We suggest that this novel mechanism enables
positive estrogen impact on the protein balance and insulin sensitivity in
skeletal muscle, thus explaining our previous observations of the
favorable effects of HRT on adipokine and glucose profile, mobility,
muscle power, and body and muscle composition in postmenopausal
women (Ronkainen et al., 2009; Ahtiainen et al., 2012b).
Although the IGF-1 pathway is one of the main regulatory pathways
in skeletal muscle (Velloso, 2008), little is known about how it is affected
by estrogen. Instead, studies with breast cancer cell lines have yielded
much evidence for this two-way cross talk between estrogen and the
IGF-1 pathway (Lee et al., 2001). Thus, estradiol is known to potentiate
the effect of IGF-1 on IGF-1R signaling (Dupont et al., 2000),
up-regulate several proteins of the IGF-I pathway (Bernard et al.,
2006), and activate IGF-IR (Song, 2007). Our recent skeletal muscle
studies have shown the estrogen and IGF-1 pathways to be linked, as
increased IGF-1 pathway activity was found in the muscle of HRT users
but not in nonusers (P€oll€anen et al., 2010; Ahtiainen et al., 2012a). This
current study gives further support for estrogen-mediated regulation of
IGF-1 signaling.
During recent years, studies related to estrogen-responsive cancers
have provided compelling evidence on the regulation via up-regulated
miRNAs by estrogen both in humans (Segura et al., 2009) and
experimental animals (Munagula et al. 2013). In skeletal muscle, miRNAs
are known to have an important role in regulation, development, and
function in health and disease (Guller & Russell, 2010), while their
hormonal regulation has remained unknown. In women, several
muscular risk factors culminate at menopause, when dramatic changes
occur in sex hormone status. Our current study reveals for the first time
that two estrogen-sensitive miRNAs regulate genes that are involved in
the IGF-1 signaling pathway in human skeletal muscle. First, the down-
regulation of miR-182 and miR-223 in the HRT users accorded with the
higher mRNA and protein expression of IGF-1R, which in all likelihood
leads to higher activity of the following PI3K/Akt-pathway in HRT users
compared to nonusers. Binding of IGF-1 to its receptor in skeletal muscle
is known to induce a cascade of downstream effects on, for example,
proliferation, differentiation, apoptosis, and glucose metabolism (Denley
et al., 2005). The activation of downstream target PI3K leads to the
activation of AKT, which further stimulates protein synthesis via mTOR.
Activation of the IGF-1 pathway also inhibits protein degradation via the
ubiquitin-proteasome system by phosphorylating and repressing the tran-
scription factors of the FOXO family (Bodine et al., 2001). In the current
study, we were able to confirm E2-mediated increment in the
phosphorylation of AKT in mouse muscle and in the phosphorylation
of mTOR in human myoblasts.
Furthermore, FOXOs are also required for another proteolytic system,
that is, the autophagy lysosome pathway (Mammucari et al., 2007)
shown to be important for disposal of damaged and toxic proteins and
dysfunctional cell organelles. Basal autophagy is highly essential for
muscle fiber homeostasis and maintenance of their integrity, while
autophagy inhibition enhances muscle loss (Masiero et al., 2009).
Specifically, the role of FOXO3A as an inducer of autophagy is supported
by the finding that transfection of adult muscle fibers with constitutively
active FOXO3A causes accumulation of autophagic vacuoles, whereas
fasting-induced autophagy is blocked by dominant-negative FOXO3A
and by RNA interference-mediated FOXO3A knockdown. Furthermore,
FOXO3A is required for the up-regulation of autophagy-related genes
such as LC3 and Bnip3 (Mammucari et al., 2007). On the other hand,
inhibition of autophagy by muscle-specific knockout of the autophagy
gene Atg7 was found to cause muscle atrophy accompanied by decrease
in muscle force with accumulation of altered mitochondria and aberrant
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concentric membranous structures. Inhibition of autophagy also exac-
erbated muscle loss during denervation and fasting suggesting that the
persistence of dysfunctional organelles affects the progression of muscle
atrophy (Masiero et al., 2009). Interestingly, a recent work by Luo et al.
(2013) demonstrated in aged animal model that resistance exercise
training up-regulated the expression of total FOXO3A, among other
mediators (Luo et al., 2013).These data suggest that the benefits of
resistance exercise are associated with increased autophagy activity
accompanied by modulation of IGF-1, the AKT/mTOR, and AKT/FOXO3A
signaling pathways in aged skeletal muscles (Luo et al., 2013). Conse-
quently, it is tempting to suggest that HRT activates in skeletal muscle
regulatory routes comparable with those affected by resistance-type
physical training.
In addition to protein homeostasis, the IGF-1-pathway plays a central
role in muscle metabolism by stimulating glucose transport and glycogen
and lipid synthesis following the activation of insulin/IGF-1 receptors
(Saltiel & Kahn, 2001). Of the myomiRs, miR-1 and miR-133a have been
connected with insulin sensitivity and glucose homeostasis (Granjon
et al., 2009; Gallagher et al., 2010). We found no differences in either
of these particular miRNAs between the twin sisters discordant for HRT
or in other miRNAs known to be involved in the insulin sensitivity of
skeletal muscle (Guay et al., 2011). Instead, we found two miRNAs, miR-
182 and -223, participating in the main pathway of the body’s glucose
homeostasis. Interestingly, the insulin/IGF-1 signaling pathway is an
important, evolutionarily conserved pathway influencing aging and
longevity. The FOXO3A gene in particular has been strongly associated
with human longevity and with many phenotypes linked to healthy
aging, among which is the preservation of insulin sensitivity (Franceschi
et al., 2005; Bonafe & Olivieri, 2009). On the strength of these studies, it
is possible that miRNA-mediated up-regulation of FOXO3A in HRT users
has a role in the previously observed signs of better glucose profile,
insulin sensitivity, and muscle condition in HRT users, but not in nonusers
(Ronkainen et al., 2009; Ahtiainen et al., 2012b).
Age-related muscle wasting and, subsequently, the development of
sarcopenia are influenced by gradually declining physical activity and by
several biological processes, such as hypogonadic hormonal changes, fat
infiltration, and insulin resistance. Aging as such is associated with
decreased circulating IGF-1 levels, decreased IGF-1R content and IGF-1R
phosphorylation in muscle, and dysfunction of the postreceptor signaling
pathways (Barbieri et al., 2003). Furthermore, the skeletal muscle
anabolic response to IGF-1 administration is weakened in the elderly
(Cao et al., 2007). Rightly, modulation of the IGF system is suggested as
a reasonable strategy to improve muscle condition in older adults. In the
present study, we confirmed that estrogen-regulated miRNAs, that is,
miR-182, miR-223 and miR-142-3p, exist in skeletal muscle of post-
menopausal women. Specifically, miR-182 and miR-223 participate in
the modulation of the insulin/IGF-1 pathway signaling. We suggest that
the observed miRNA-mediated enhancement of the target genes’ IGF-1R
and FOXO3A expression as well as activation of IGF-1 pathway signaling
via phosphorylation of AKT and mTOR is an important mechanism for
positive estrogen impact on skeletal muscle in postmenopausal women
using hormone replacement therapy.
Experimental procedures
Study design and participants
This study is a part of a larger research project, ‘Sarcopenia and Skeletal
Muscle Adaptation to Postmenopausal Hypogonadism: Effects of Phys-
ical Activity and Hormone Replacement Therapy in Older Women – a
Genetic and Molecular Biology Study on Physical Activity and Estrogen-
related Pathways’ (SAWEs), designed to investigate the molecular events
involved in maintaining proper muscle mass and functions postmeno-
pause (Ronkainen et al., 2009). The participants for this study were
recruited from the Finnish Twin Cohort (n = 13 888 pairs) (Kaprio &
Koskenvuo, 2002). An invitation was sent to all MZ female twin pairs
born in 1943–1952 (n = 537 pairs). Only twin pairs in which one co-twin
was a current HRT user and the other co-twin was not currently using
HRT were invited to respond to the invitation. Of all the responders
(n = 114 pairs), twin pairs where one sister had never used HRT, while
the other sister was a current user, and who reported willingness to
participate in the laboratory measurements, were contacted (n = 21
pairs). Finally, a total of 16 MZ pairs aged 54–62 years discordant for
HRT use and without any predefined contraindications participated in
the study, as described previously (Ronkainen et al., 2009). One twin
pair turned out to be dizygotic and was excluded from the further
analyses. Consequently, 15 pairs of HRT discordant MZ twin pairs aged
57.8  2.0 years were finally included to the study group. The HRT
users consisted of five women using estradiol-only preparations
(1–2 mg), six women on combined treatment including estrogenic
(1–2 mg) and progestogenic compounds, and four women using
tibolone (2.5 mg). In the present study, our focus was on estrogen
deprivation and replacement (estradiol-only plus combined treatments).
Therefore, tibolone users were excluded from the study. The mean
duration of HRT usage was 7.5  3.9 years (range 2–16 years) in twin
pairs from whom muscle samples were available.
(B)(A)
Fig. 7 The effects of estrogen stimulation on miRNA transcripts and phosphorylation of AKT protein in young male mouse diaphragm muscle. (A) qPCR analyses of miRNA
transcripts normalized to U6B in mouse muscle stripes treated with 100 nM estradiol or mock for 24 h. (B) Western blot analysis of phosphorylated AKT and total AKT in
mouse muscles treated with 100 nM estradiol for 24 h. The amount of phosphorylated AKT was analyzed by densitometry and normalized against AKT expression. Data are
presented as percentage of control (mock) and reported as means  SD of three independent experiments. OD indicates optical density. t-test, *P < 0.05.
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Estradiol measurement
Serum E2 levels were assessed in duplicate by extraction RIA qualified for
low serum steroid levels, as described previously (Ankarberg-Lindgren &
Norjavaara, 2008).
Body and thigh muscle composition
Body mass index (BMI) was calculated from height and weight measured
with standard procedures. Percentage body fat was measured with
bioelectrical impedance [InBody (720), Biospace Co. Ltd., Seoul, Korea].
Computed tomography (CT) scans (Siemens Somatom Emotion scanner,
Siemens AG, Erlangen, Germany) of the thigh were obtained from the
midpoint between the greater trochanter and the lateral joint line of
the knee. The scans were analyzed using software developed at the
University of Jyv€askyl€a (Jyv€askyl€a, Finland) for cross-sectional CT image
analysis (Geanie 2.1, Commit Ltd, Espoo, Finland). The software
separates fat and lean tissue based on given radiological density limits.
Total thigh muscle and fat cross-sectional areas (CSA) were analyzed,
and the relative proportion of muscle in the CSA of the whole thigh was
calculated. Muscle power, that is, the ability of the neuromuscular
system to produce the greatest possible force as rapidly as possible, was
assessed as vertical jumping height on a contact mat, as described
previously (Ronkainen et al., 2009).
Muscle tissue sampling and myoblast cell culture
Muscle (m. vastus lateralis) needle biopsies from the study subjects were
taken under standard fasted conditions under local anesthesia with
supine participants. Tissue samples were snap frozen and stored at
80 °C for further analyses.
Primary human muscle cell line (myoblasts) obtained from quadriceps
femoris muscle biopsy of a 5-day-old, healthy female infant was kindly
provided by Dr Gillian Butler-Browne and Dr Vincent Mouly. Myoblast
cells were maintained and cultivated in phenol-free DMEM supple-
mented with 20% 199 medium, 20% fetal bovine serum, and
50 lg mL1 gentamycin (all from Life Technologies, Carlsbad, CA, USA).
Diaphragm muscles from 2-month-old male mice were excised and
divided into stripes of approximately 10 mg. Stripes of muscles were
placed onto culture plates in serum-free DMEM so that the muscle piece
was covered by the medium.
MiRNA profiling
Mature miRNA profiling was performed using an Applied Biosystems
7900 HT real-time PCR instrument and human MicroRNA Array pool A
(Applied Biosystems, Foster City, CA, USA), containing 365 different,
most common human miRNA assays in addition to selected small
nucleolar RNAs (snoRNAs). RNA was converted to cDNA by priming with
a mixture of looped primers (MegaPlex kit, Applied Biosystems) in
compliance with the manufacturer’s instructions. Preamplification was
performed using 3 lL of input RNA with PreAmp kit (Applied Biosys-
tems). 9 lL of preamplified cDNA was used for RT–PCR with MicroRNA
Array pool A.
qPCR validation
Real-time quantitation to measure miRNA expression was performed
with the TaqMan miRNA reverse transcription kit and miRNA assay
(Applied Biosystems) with some modifications. Briefly, total RNA was
reverse transcribed (RT) by a TaqMan MicroRNA RT kit. 5 lL of RT
reactions contained 1 lL of each miR-specific stem-loop primer, 1.67 lL
of input RNA, 0.4 lL of 10 mM dNTPs, 0.3 lL of reverse transcriptase,
0.5 lL of 10 9 buffer, 0.6 lL of RNAse inhibitor diluted 1:10, and
0.5 lL of H2O2. The mixture was incubated at 16 °C for 30 min, at
42 °C for 30 min, and at 85 °C for 5 min. Subsequently, quantitative
real-time PCR was performed. For 5 lL of PCR reaction, 0.25 lL of 20x
TaqMan MicroRNA Assay containing PCR primers and probes (50-FAM),
2.75 lL of 2x TaqMan Universal Master mix, no UNG (Applied
Biosystems), and 2.25 lL of RT product was mixed. The reaction was
first incubated at 95 °C for 2 min followed by 40 cycles of 95 °C for
15 min and 60 °C for 1 min. Data were analyzed with real-time PCR
Opticon Monitor version 2 (MJ Research, Waltham, MA, USA), with the
automatic Ct (cycle threshold) setting for adapting baseline and
threshold for Ct determination. MiRNA fold changes between different
groups were calculated by the delta Ct method. U44 small nucleolar RNA
(RNU44) was used as the housekeeping small RNA reference gene. Each
reaction was performed in duplicate.
Putative targets identification
To increase speed and accuracy of the identification of putative mRNA
targets common to more than one miR, a computer program, named
SID1.0 (simple String IDentifier), previously developed by our group, was
used (Albertini et al., 2011). This program is based on an exhaustive
search strategy and is specifically designed to screen shared data (target
genes, miRs and pathways) available from the PicTar and DIANA-MicroT
3.0 databases. Common pathways of specific miRs were identified using
the DIANA-microT 3.0 target prediction program (http://diana.cslab.ece.
ntua.gr/microT/).
Gene expression analysis
Total RNA from muscle tissue samples, myoblasts, and MCF-7 cells was
extracted using Trizol reagent (Invitrogen,Carlsbad, CA,USA). For the qPCR
analysis,onemicrogramofRNAwas reverse transcribed intocDNA(TaqMan
Reverse Transcription Reagents, N808-0234, Applied Biosystems). TaqMan
Gene Expression Assays (Applied Biosystems) were used to investigate the
expression of IGF-1R (Hs99999020_m1), FOXO1A (Hs01054576_m1), and
FOXO3A (Hs00818121_m1). Assays were performed with an Applied
Biosystems ABI 7300 unit using standard PCR conditions as recommended
by the manufacturer. Samples were run in triplicate, and the reference
sample was included in all plates to control for interassay variation. GAPDH
(Hs99999905_m1) was used for endogenous control.
Western immunoblot analyses
For human muscle samples, total proteins were extracted using tissue
extraction reagent I-buffer (Invitrogen) supplemented with protease and
phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL, USA).
Total proteins from cell experiments and mouse muscle were extracted
using RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1.0%
Triton X-100, 5 mM EDTA, pH 8.0) containing protease inhibitor cocktail
(Roche Applied Science, IN, USA). Protein concentration was determined
using Pierce BCA-assay for human muscle samples and myoblasts and
Bradford Reagent (Sigma-Aldrich, St Louis, MO, USA) for other exper-
iments. Total protein extracts (40 lg) were separated by Criterion TGX
precast gels 4–20% (human muscle/myoblasts) or by 10% SDS-PAGE
(MCF-7 cells/mouse muscle) and transferred to nitrocellulose or PVDF
membrane (Whatman, Dassel, Germany). For human muscle and
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myoblast Western blots, the membranes were blocked in Odyssey
blocking buffer (LI-COR, Licoln, NE, USA) and washed in PBS with 0.1%
Tween-20 (PBS-T) before incubation with primary antibodies against
FOXO3A, IGF-1R, p-AKT, or p-mTOR diluted 1:1000 (Cell Signalling
Technology, Beverly, MA, USA). GAPDH antibody diluted 1:40000 was
used to control loading and quantitation (Sigma-Aldrich, St Louis, MO,
USA). IRDye 800CW donkey anti-rabbit IgG (LI-COR) was used as
secondary antibody, and proteins were visualized and quantified using
Odyssey CLx (LI-COR). For the MCF-7 cell and mouse muscle experi-
ments, membranes were blocked in TBS with 0.1% Tween-20 (TBS-T)
containing 5% fat-free dry milk for 60 min and then incubated
overnight at 4 °C with rabbit polyclonal primary antibodies against
FOXO1A, FOXO3A, IGF-1R, p-AKT, and total AKT diluted 1:1000 (Cell
Signalling Technology) and against b-actin diluted 1:10000 (Santa Cruz,
CA), which was used to check the uniformity of blotting. Membranes
were washed in TBS-T and incubated 60 min with secondary antibody
diluted 1:10000 (Sigma-Aldrich) followed by washing in TBS-T. Proteins
were visualized by ECL as instructed by the manufacturer (Amersham,
Piscataway, NJ, USA) and quantified using Quantity One software (Bio-
Rad Laboratories, Hercules, CA, USA).
Experiments for phosphorylation of AKT and mTOR
Myoblasts were treated for 72 h with 10 nM E2, 100 nM E2, or solvent
alone and analyzed in Western blots to detect phosphorylation of AKT
(SER 473, Cell Signalling #9271) and mTOR (SER 2448, Cell Signalling
#2971). Phosphorylation was visualized and quantified using Odyssey
CLx (LI-COR). GAPDH (Sigma-Aldrich) was used to standardize loading.
Stripes of mouse diaphragms were exposed either to 100 nM E2 or
solvent alone for 24 h. Stripes were homogenized and lysed in RIPA
buffer containing phosphatase and proteases inhibitors (mini cOmplete
and PhosSTOP, Roche) and analyzed by Western blots to detect SER 473
phosphorylation of AKT. Image-J was used to compute densitometry of
bands. Total AKT (Cell Signalling #9272) was used to standardize
loading.
Binding analyses (Luciferase Activity assay)
The rationale of this assay is based on the translational inhibition of the
firefly luciferase gene by cloning of miRNA-targeted sequences in its
30UTR (30untranslated regions). P-CMV-MIR182, p-CMV-MIR223, and
p-CMV-MIR (empty vector) plasmids were shipped from OriGene
(OriGene Technologies Inc., Rockville, MD, USA). The plasmids used in
the luciferase assays were generated by cloning oligonucleotides bearing
wild-type (wt) or deleted (del) miR-182/223 target pairing site of IGF-1R,
FOXO1A, and FOXO3A genes downstream of the stop codon in pMIR-
REPORT-Luciferase (pLUC, Ambion Inc., Austin, Texas, USA), between
the SpeI and HindIII restriction sites. The sequences of the oligonucle-
otides (50-30) used for the luciferase activity assays are presented in Table
S2. HEK-293 cells were transfected with 100 ng of pLUC, pLUC-182/
223-target or pLUC-182/223-target-del, 0.9 lg of pCMV-MIR182/223
and pCMV-MIR, and 50 ng of pRL-null renilla luciferase. Cellular extracts
were tested with the Dual Luciferase Assay (Promega Corp, Madison,
WI, USA), according to the manufacturer’s instructions, 48 h after
transfection, using a Synergy HT luminometer (BioTek Instruments Inc,
Winooski, VT, USA). Values were normalized according to renilla
luciferase activity, and the ratio of firefly luciferase activity of each
construct was calculated either in the presence or in the absence of
exogenous miR-182/223.
Functional analyses
MCF-7 cells (human breast adenocarcinoma cell line) were used for the
functional assay. MCF-7 cells are one of the in vitro models most widely
used to study E2-signaling, as they express high levels of ERa and are
strongly growth-stimulated by E2. MCF-7 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Euroclone, Milano, Italy)
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/
streptomycin, and 1% L-glutamine (Euroclone). Three days before the
experiments, the cells were switched to phenol red-free DMEM (Sigma-
Aldrich) containing 10% charcoal/dextran-stripped FBS (Sigma-Aldrich),
1% penicillin/streptomycin, and 1% L-glutamine (Euroclone). Where
indicated, treatments included vehicle control (100% EtOH) and 17b-
estradiol (10 or 100 nM; Sigma-Aldrich) for 72 h. Transient transfection
of miRs was performed with FuGENE transfection reagent (Roche
Applied Science, Indianapolis, USA), according to the manufacturer’s
instructions. In brief, 8 9 104 cells were plated in 6-well plates and kept
overnight for attachment. The next day, the cells were transfected with
pCMV-MIR182/223 and pCMV-MIR (OriGene) or mirVanaTM miRNA
inhibitors (Ambion, USA) hsa-miR-223 ID:MH12301 (miR-223 antago-
mir), anti-miR negative control #1 (Mock) (Fig 3). The FuGENE transfec-
tion method was optimized by testing different quantities of reagent and
miR; FuGENE (lL)/miR (lg) ratios of 3:1 in particular were found to be
optimal. Hormonal treatments were initiated 48 h after transfection. The
medium was changed 72 h after transfection with fresh phenol red-free
DMEM supplemented with 0.5% charcoal/dextran-stripped FBS.
Statistical analysis
MiRNAs expressed at a detectable level in more than 80% of samples in
the microRNA array were included in the final data analysis. As a
normalization correction factor, the miRNAs were compared based on
their expression relative to the overall miRNA expression on each array,
using median normalization analysis (DCt). MiRNAs showing a difference
in mean DCt higher than 1.5 (DDCt > 1.5 and DDCt < 1.5) between
the studied groups were selected. Fold change was calculated based on
the estimated mean difference (2^(-DDCT)). The statistical analyses for
the group comparisons included either paired-samples t-test or non-
parametric Wilcoxon signed ranks tests, depending on the normal
distribution of the means tested by the Shapiro–Wilk-test. P values less
than 0.05 were considered significant.
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